RT Journal Article
SR Electronic
T1 Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure
JF Gut
JO Gut
FD BMJ Publishing Group Ltd and British Society of Gastroenterology
SP 559
OP 563
DO 10.1136/gut.45.4.559
VO 45
IS 4
A1 P B Jeppesen
A1 B Hartmann
A1 B S Hansen
A1 J Thulesen
A1 J J Holst
A1 P B Mortensen
YR 1999
UL http://gut.bmj.com/content/45/4/559.abstract
AB BACKGROUND Glucagon-like peptide 2 (GLP-2) is a growth factor for the intestinal epithelium in rodents and may affect intestinal transit.AIMS To study the GLP-2 response to nutrient ingestion in seven short bowel patients with intestinal failure and seven controls.METHODS The patients and controls were admitted twice for two test meals after a night of fasting. Meal A was liquid (300 ml, 1.88 MJ); meal B was a regular breakfast (755 g, 3.92 MJ). Plasma samples were collected for 180 minutes; GLP-2 immunoreactivity was measured with an NH2 terminal specific radioimmunoassay.RESULTS Both meals elicited significant increases in plasma GLP-2 in controls. The magnitude and duration of the responses were dependent on the meal size: the maximum median (25–75%) increases after meal A and B were 24 (3–28) and 48 (33–56) pmol/l. Plasma GLP-2 returned to basal concentrations 180 minutes after meal A, but remained at 50% of peak values after meal B. In the patients neither meal significantly changed the GLP-2 concentration; the maximum median elevation after meal B was 5 (2–8) pmol/l. There were significant differences between patients and controls with respect to the GLP-2 responses to meals A and B.CONCLUSION Identification of GLP-2 as a tissue specific intestinal growth factor and demonstration of an impaired meal stimulated GLP-2 response in short bowel patients raises the possibility that GLP-2 administration may constitute a new therapeutic strategy, enhancing jejunal adaptation in ileum resected short bowel patients with intestinal failure.BEEbasal energy expenditureGLP-2glucagon-like peptide 2PGDPproglucagon derived peptides